“Our experience supports the use of ruxolitinib as an effective...

First 112 Last

Share
Profile

Follow
Far Away Red

659 Posts.

209

02/12/23

12:02

Post #: 71233553
Share
Originally posted by whytee: ↑

No. The 2-year overall survival was 71.9% (CI 95% 58.6-85.2)
Better than the claims for Remestemcel.
"Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity

Yasmina Mozo¹, David Bueno¹, Luisa Sisinni¹, Alba Fernández-Arroyo¹, Blanca Rosich¹, Antonio Pérez Martínez¹, María Isabel Benítez-Carabante², Laura Alonso², María Luz Uría², Cristina Díaz de Heredia², Carmen Mestre-Duran³, Cristina Ferreras Bárbara Pascual³, Juan Torres⁴, Itsaso Losantos⁵, Adela Escudero⁶, Beatriz Ruz-Caracuel⁶
Affiliations
PMID: 33661711
DOI: 10.1080/08880018.2020.1868637
Abstract

Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population showing efficacy against GvHD. In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after HSCT from two Pediatric Hemato-Oncology Departments in Spain between March 2017 and December 2018. Patients received a median number of 4 (IQR 2) previous lines of treatment before starting ruxolitinib. The overall response rate in acute GvHD (aGvHD) and cGvHD was 87% and 91%, respectively. Complete response (CR) was observed in 37% of aGvHD and 8.3% of cGvHD. Remarkably, 43% and 40% of patients with steroid-refractory gastrointestinal aGvHD and lung cGvHD achieved CR. During ruxolitinib treatment, there were 36%, 31%, and 10% infections caused by viruses, bacteria, and fungi, respectively. Overall, four patients interrupted ruxolitinib due to infectious complications, hematological, and liver toxicity. The 2-year overall survival was 71.9% (CI 95% 58.6-85.2). Our experience supports the use of ruxolitinib as an effective treatment for steroid-refractory acute and cGvHD in children with a moderate toxicity profile"

Expand

“Our experience supports the use of ruxolitinib as an effective treatment for steroid-refractory acute and cGvHD in children with a moderate toxicity profile”

Hmm, you and your cohort have dug out a study on Ruxolitinib from 2021 to get over your point that it is an effective treatment. Considering, that you’re constantly criticising MSB for conducting post hoc analysis of clinical trials to suit your null hypothesis agenda, I find it a bit rich that you are using this study for your own ends.

That sentence picked out smacks of post hoc analysis if ever I saw it. You can’t have it both ways so care to elaborate?
MSB Price at posting: 40.5¢ Sentiment: None Disclosure: Held
11 Upvote

0 Great analysis

Reply